BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23009936)

  • 1. Role of germline genetic factors in MPN pathogenesis.
    Harutyunyan AS; Kralovics R
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1037-51. PubMed ID: 23009936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms.
    Bellanné-Chantelot C; Rabadan Moraes G; Schmaltz-Panneau B; Marty C; Vainchenker W; Plo I
    Blood Rev; 2020 Jul; 42():100710. PubMed ID: 32532454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.
    Abdel-Wahab O; Tefferi A; Levine RL
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1053-64. PubMed ID: 23009937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Genetic Makeup of Myeloproliferative Neoplasms: Role of Germline Variants in Defining Disease Risk, Phenotypic Diversity and Outcome.
    Masselli E; Pozzi G; Carubbi C; Vitale M
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of mutations in myeloproliferative neoplasms.
    Levine RL
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):489-94. PubMed ID: 19959098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited predisposition to myeloproliferative neoplasms.
    Jones AV; Cross NC
    Ther Adv Hematol; 2013 Aug; 4(4):237-53. PubMed ID: 23926457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
    Takenaka K
    Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
    Cuthbert D; Stein BL
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):65-73. PubMed ID: 30927977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms.
    Jäger R; Kralovics R
    Curr Cancer Drug Targets; 2011 Jan; 11(1):20-30. PubMed ID: 21062246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
    Kreipe HH
    Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
    Tallarico M; Odenike O
    Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene mutations in myeloproliferative neoplasms].
    Araki M; Morishita S; Komatsu N
    Rinsho Ketsueki; 2016; 57(12):2526-2534. PubMed ID: 28090022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.